Navigation Links
XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Date:3/18/2009

REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that it has entered into an asset purchase agreement with Bio-GAL Ltd, a private company, for the rights to a use patent on Recombinant Erythropoietin ("rHuEPO") for the prolongation of multiple myeloma ("MM") patients' survival and improvement of their quality of life.

MM is a severe plasma cell malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to the gradual replacement of normal hematopoiesis.

David Grossman, XTL's co-Chief Executive Officer, commented, "This is a very exciting opportunity to acquire the rights for a potential treatment for a severe and incurable blood cancer. We at XTL are thrilled at this opportunity and expect to embark on a clinical trial with rHuEPO for the treatment of MM in the near term and hope to lead it to a successful outcome."

In accordance with the terms of the asset purchase agreement, XTL will issue Bio-GAL Ltd. ordinary shares representing just under 50% of the current issued and outstanding share capital of the Company. In addition, XTL will make milestone payments of approximately $10 million in cash upon the successful completion a Phase 2 clinical trial. The Company's Board of Directors may, in its sole discretion, issue additional ordinary shares to Bio-GAL Ltd in lieu of such milestone payment. XTL is also obligated to pay 1% royalties on net sales of the product. The closing of the transaction is subject to various conditions including XTL's and Bio-GAL's shareholders' approvals, as well as completion of a financing. Closing is expected to take place in the second or third quarter of 2009.

ABOUT ERYTHROPOIETIN (EPO)

Erythropoietin (EPO) is a glyco
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
6. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
10. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. ... of protective clothing for industry, healthcare and to first ... release its financial results for the fiscal 2013 fourth ... May 21, 2013 at stock market close and will ... 4:30 p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ...
(Date:5/17/2013)... 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... at the UBS Global Healthcare Conference in New ... 22 nd at 11 a.m. Eastern Time. To listen ... please visit the Investor Relations section of the Company,s Web ... for 14 days after the event. About Orexigen® ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
(Date:5/18/2013)... (May 19, 2013) Each year, the American ... outstanding contributions and achievements in gastroenterology through its ... many distinguished and talented individuals who work tirelessly ... Today, we are pleased to announce the 2013 ... their colleagues for their tremendous contributions to our ...
(Date:5/18/2013)... 2013 Illuminations is proud to present the ... Seminars will take place over the course of four days, ... and Saturday, June 8, 2013. , Inner Child Therapy is ... on the attitudes, patterns and coping mechanisms that create the ... learn to live a more integrated and balanced life style, ...
(Date:5/18/2013)... MOOSGO.COM published an original art book for iPad ... group of artists who share their creations based on the ... Exclusively for iPad . , This work gathers ... that reflect the signature idiosyncrasy and passion of tango. Such ... Store and it includes a free trailer of the ...
(Date:5/18/2013)... In a May 14, 2013 article ... After Discovering Cancer Gene,” Fox News reported the movie ... that she carried a gene that doctors estimated gave ... a 50 percent risk of ovarian cancer (go to: ... 16, 2013 with a blog post entitled “A Patient’s ...
(Date:5/18/2013)... Transvaginal mesh lawsuits involving ... forward in a consolidated litigation underway in New Jersey’s ... to a notice on the Court’s website, the next ... will be held on Wednesday, May 22nd. Court ... the proceeding on behalf of women who suffered serious ...
Breaking Medicine News(10 mins):Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:New Art Book for iPad: Tango Art 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... SINGAPORE, Nov. 2 /PRNewswire-Asia/ -- GfK Asia releases ... line with the,17th Hong Kong Optical Fair, hosted by Hong ... 2009 include China, Hong Kong, Korea,Singapore and Malaysia. The survey ... or the same in 2010. , ...
... cocoa, snuggling under blankets and heart attacks all have in ... months. , According to the Centers for Disease Control ... heart attack or similar cardiac event during or after a ... create awareness, work to lower that number, and highlight other ...
... professional athletes, who wear helmets in their careers, to help ... NEW YORK, Nov. 2 November is Epilepsy Awareness Month. ... American Epilepsy Outreach Foundation (AEOF) has joined with ... 1st Annual Helmets for Hope(TM) Campaign. The Helmets for Hope(TM) ...
... 2 In a dramatic settlement seen as a novel ... professional association, and one of the country,s biggest hospital systems ... on containing the spread of pandemics such as H1N1 "swine ... new course for limiting the spread of not only swine ...
... Preliminary evaluation after completion of treatment phase shows that, ... for patients with advanced-stage, platinum-resistant, taxane-pretreated ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ) ... therapy and oncology, today announced positive efficacy data from ...
Cached Medicine News:Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Asian Optical Retailers Upbeat about 2010 2Health News:Asian Optical Retailers Upbeat about 2010 3Health News:MTD Joins Forces with the AHA to Promote Heart Health 2Health News:Helmets for Hope Campaign and Gala 2Health News:Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures 2Health News:Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
Classic black cast boot with unisex styling...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
The Multi-Purpose Medical-Surgical Shoe...
Medicine Products: